NICE to name and shame PCTs

NICE is to publish details of individual PCTs' uptake of clinical guidance.

In November NICE will, for the first time, publish the details of the level of uptake of NICE-approved drugs by all PCTs, SHAs and cancer networks.

NICE's report will compare the level of uptake of medicines with the institute’s estimate of what level of uptake it would expect for each organisation.

The report will be published as part of the government’s drug pricing agreement with the pharmaceutical industry.

As part of the drug pricing scheme, the government agreed to publish a review of uptake of NICE-appraised medicines.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in